Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864143 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,320
- Enrollment target
NCT06864143: Completed Phase 2 study, sponsored by ModernaTX.
NCT06864143 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 1,320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (892% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06864143, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Interventions
- BIOLOGICAL mRNA-1083 Composition 1 Dose A Lot A
- BIOLOGICAL mRNA-1083 Composition 1 Dose A Lot B
- BIOLOGICAL mRNA-1083 Composition 1 Dose B
- BIOLOGICAL mRNA-1083 Composition 1 Dose C
- BIOLOGICAL mRNA-1083 Composition 2 Dose A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 2 |
What the finished NCT06864143 record still lists
NCT06864143 is an interventional study that assigns participants to a tested intervention. Its 1,320 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (892% higher).
The record links to 0 conditions, and to 5 interventions - of which mRNA-1083 Composition 1 Dose A Lot A is the first listed.
NCT06864143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06864143 about?
NCT06864143 is a clinical study titled "A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age". The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
What is the current status of trial NCT06864143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,320 participants. The study started on 2025-03-07. Estimated completion is 2025-10-13.
What interventions are being tested in trial NCT06864143?
The interventions under investigation include: mRNA-1083 Composition 1 Dose A Lot A (BIOLOGICAL), mRNA-1083 Composition 1 Dose A Lot B (BIOLOGICAL), mRNA-1083 Composition 1 Dose B (BIOLOGICAL), mRNA-1083 Composition 1 Dose C (BIOLOGICAL), mRNA-1083 Composition 2 Dose A (BIOLOGICAL).
Who is sponsoring clinical trial NCT06864143?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06864143's enrollment target sits among peer trials
1,320 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI